Advances in DNA repair in cancer therapy
https://libcat.nshealth.ca/en/permalink/provcat32399
Lawrence Panasci, Raquel Aloyz, Moulay Alaoui-Jamali, editors.
--New York, NY:
Springer
, c2013.
- Available Online
- View e-Book
- Location
- Online
This book deals with the emerging role of various DNA repair proteins and the regulatory elements which are implicated in cancer therapy such as DNA cross-linking agents, radiotherapy and bleomycin. The DNA repair genes discussed include those involved in BRCA/Rad51-related homologous recombinational repair, DNA-PK related nonhomologous endjoining and the nucleotide excision repair gene, ERCC1. Moreover, the role of regulatory genes such as PARP, ATR, telomerase, growth factor receptors and dow…
- Available Online
- View e-Book
- Other Authors
- Panasci, Lawrence
- Aloyz, Raquel
- Alaoui-Jamali, Moulay
- Responsibility
- Lawrence Panasci, Raquel Aloyz, Moulay Alaoui-Jamali, editors
- Place of Publication
- New York, NY
- Publisher
- Springer
- Date of Publication
- c2013
- Physical Description
- 1 online resource (viii, 312 p. : 35 ill., 25 ill. in color)
- Series Vol.
- 72
- Series Title
- Cancer drug discovery and development
- ISBN
- 9781461447412
- Subjects (MeSH)
- Antineoplastic Agents - therapeutic use
- DNA Repair
- Neoplasms - drug therapy
- Neoplasms - genetics
- Subjects (LCSH)
- Oncology
- Abstract
- This book deals with the emerging role of various DNA repair proteins and the regulatory elements which are implicated in cancer therapy such as DNA cross-linking agents, radiotherapy and bleomycin. The DNA repair genes discussed include those involved in BRCA/Rad51-related homologous recombinational repair, DNA-PK related nonhomologous endjoining and the nucleotide excision repair gene, ERCC1. Moreover, the role of regulatory genes such as PARP, ATR, telomerase, growth factor receptors and downstream kinase signalling is examined.
- Contents
- Repair of DNA interstrand cross-links produced by cancer chemotherapeutic drugs -- DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy -- Growth factor receptor signaling, DNA damage response, and cancer cell susceptibility to chemotherapy and relapses -- Relationship between DNA-repair genes, cellular radiosensitivity, and the response of tumors annd normal tissues to radiotherapy -- Important roles of ERCCI in DNA repair and targeted therapy -- The role of BRCA1 and BRCA2 in anticancer drug therepy -- DNA-PK in CLL chemotherapy -- Poly (ADP) ribose polymerase at the interface of DNA damage signaling and DNA repair -- Cellular protection against the antitumor drug bleomycin -- ATR as a therapeutic target -- Telomores, Telomerase, and DNA damage response in cancer therapy -- RAD51 is a key protein of DNA repair and homologous recombination in humans -- Index.
- Format
- e-Book
- Location
- Online
ALERT – adverse late effects of cancer treatment. Volume 1, General concepts and specific precepts
https://libcat.nshealth.ca/en/permalink/provcat33390
Philip Rubin, Louis S. Constine, Lawrence B. Marks, editors.
--Heidelberg:
Springer
, c2014.
- Available Online
- View e-Book
- Location
- Online
The literature on the late effects of cancer treatment is widely scattered in different journals since all major organ systems are affected and management is based on a variety of medical and surgical treatments. The aim of ALERT Adverse Late Effects of Cancer Treatment is to offer a coherent multidisciplinary approach to the care of cancer survivors. The central paradigm is that cytotoxic multimodal therapy results in a perpetual cascade of events that affects each major organ system different…
- Available Online
- View e-Book
- Other Authors
- Rubin, Philip
- Constine, Louis S
- Marks, Lawrence B
- Responsibility
- Philip Rubin, Louis S. Constine, Lawrence B. Marks, editors
- Alternate Title
- Adverse late effects of cancer treatment
- Place of Publication
- Heidelberg
- Publisher
- Springer
- Date of Publication
- c2014
- Physical Description
- 1 online resource (xxiv, 311 pages)
- Series
- Medical radiology. Radiation oncology
- Series Title
- Medical radiology (Series)
- ISBN
- 9783540723141 (electronic bk.)
- 9783540723134
- Subjects (MeSH)
- Antineoplastic Agents - adverse effects
- Radiotherapy - adverse effects
- Radiation Injuries
- Subjects (LCSH)
- Cancer - Treatment - Complications
- Antineoplastic Agents - adverse effects
- Radiotherapy - adverse effects
- Abstract
- The literature on the late effects of cancer treatment is widely scattered in different journals since all major organ systems are affected and management is based on a variety of medical and surgical treatments. The aim of ALERT Adverse Late Effects of Cancer Treatment is to offer a coherent multidisciplinary approach to the care of cancer survivors. The central paradigm is that cytotoxic multimodal therapy results in a perpetual cascade of events that affects each major organ system differently and is expressed continually over time. Essentially, radiation and chemotherapy are intense biologic modifiers that allow for cancer cure and cancer survivorship but accelerate senescence of normal tissues and increase the incidence of age-related diseases and second malignant tumors. Volume 1 of this two-volume work focuses on the general concepts and principles relevant to late effects and on the dynamic interplay of molecular, cytologic and histopathologic events that lead to altered physiologic and metabolic functions and their clinical manifestations. Chapters are also included on legal issues, economic aspects, nursing, psychological issues and quality of life.
- Contents
- Prologue: Surviving Cancer: SEER Statistics -- Biocontinuum of the Pathophysiology Paradigm -- Biophysiopathology of the Microvasculature and Microcirculation -- Molecular Mechanisms of Radiation Induced Injury -- Biodetection and Biointervention: Cytokine Pathways as a Rationale for Anti-Cytokine Interventions Post-Radiation -- Quantitative/Objective Analyses of RT-Induced Late Normal Tissue Injury Using Functional Imaging -- Biograding of Normal Tissue TNM Toxicity Taxonomy: Scoring the Adverse Effects of Cancer Treatment -- Understanding and Predicting Radiation-Associated Normal Tissue Injury: A Global and Historical Perspective -- Biotoxicity of Chemotherapy -- BioSurveillance and Longitudinal Lifelong Guidelines -- BioPediatric Complexities of Growth and Development -- BioGenetic and Host Implications -- Bioengineering of Irradiated Normal Tissues by Bone Marrow Stem Cells -- Radiotherapy-Induced Carcinogenesis and Leukemogenesis: Mechanisms and Quantitative Modeling -- The Bioepidemiology of MultiplePrimary Cancers -- Radiation-Related Second Primary Cancers: Clinical Perspectives -- The Psychosocial and Functional Impact of Radiation Therapy -- Nursing -- Economic Consequences of Late Effects -- Radiological and Nuclear Terrorism: Relevance to the Radiation Oncology and Biology Communities.
- Format
- e-Book
- Location
- Online
ALERT – adverse late effects of cancer treatment. Volume 2, Normal tissue specific sites and systems
https://libcat.nshealth.ca/en/permalink/provcat33418
Philip Rubin, Louis S. Constine, Lawrence B. Marks, editors.
--Heidelberg:
Springer
, c2014.
- Available Online
- View e-Book
- Location
- Online
The literature on the late effects of cancer treatment is widely scattered in different journals since all major organ systems are affected and management is based on a variety of medical and surgical treatments. The aim of ALERT Adverse Late Effects of Cancer Treatment is to offer a coherent multidisciplinary approach to the care of cancer survivors. The central paradigm is that cytotoxic multimodal therapy results in a perpetual cascade of events that affects each major organ system different…
- Available Online
- View e-Book
- Other Authors
- Rubin, Philip
- Constine, Louis S
- Marks, Lawrence B
- Responsibility
- Philip Rubin, Louis S. Constine, Lawrence B. Marks, editors
- Alternate Title
- Adverse late effects of cancer treatment
- Place of Publication
- Heidelberg
- Publisher
- Springer
- Date of Publication
- c2014
- Physical Description
- 1 online resource (xx, 700 pages)
- Series
- Medical radiology. Radiation oncology
- Series Title
- Medical radiology (Series)
- ISBN
- 9783540758631 (electronic bk.)
- 9783540758624
- Subjects (MeSH)
- Antineoplastic Agents - adverse effects
- Radiotherapy - adverse effects
- Radiation Injuries
- Abstract
- The literature on the late effects of cancer treatment is widely scattered in different journals since all major organ systems are affected and management is based on a variety of medical and surgical treatments. The aim of ALERT Adverse Late Effects of Cancer Treatment is to offer a coherent multidisciplinary approach to the care of cancer survivors. The central paradigm is that cytotoxic multimodal therapy results in a perpetual cascade of events that affects each major organ system differently and is expressed continually over time. Essentially, radiation and chemotherapy are intense biologic modifiers that allow for cancer cure and cancer survivorship but accelerate senescence of normal tissues and increase the incidence of age-related diseases and second malignant tumors. Volume 2 of this two-volume work comprehensively documents potential late effects in all the normal tissue anatomic sites in the human body. The detection, diagnosis, management and prevention of effects are all considered in detail, and prognostic outcomes are discussed. Radiation risk factors and interactions with chemotherapy effects are clearly presented. The text is accompanied by numerous supportive illustrations and tables.
- Contents
- Brain and Cranial Nerves -- Spinal Cord and Peripheral Nervous System -- Neuroendocrine Complications of Radiation and Cancer Therapy -- Eye and Orbit -- Radiation-Induced Ototoxicity -- Late Oral Adverse Effects of Cancer Treatments -- Upper Respiratory and Digestive System: Pharynx, Larynx, and Xerostomia -- Thyroid -- Skin Surface, Dermis, and Wound Healing -- Breast Cancer -- Lung -- Heart, Coronary Arteries, Aorta and Great Vessels, Arteries and Veins, Microcirculation -- Esophagus -- Stomach, Small and Large Intestines -- Liver -- Adverse Late Effects of Radiation Treatment in the Pancreas -- Kidney and Ureter -- Urinary Bladder -- Prostate, Seminal Vesicle, Penis, and Urethra -- The Testes -- Ovary, Uterus (Fallopian Tube, Cervix), Vagina, and Vulva -- Radiation Induced Rectal Toxicity -- Musculoskeletal System: Growing Endochondral Bone, Mature Osseous, Muscle (Striated), and Soft Tissue Mesenchyme -- Hematopoietic System -- Late Effects of Hematopoietic Cell Transplantation Including Total Body Irradiation -- Lymph Nodes, Thymus, Spleen, and Lymphatics.
- Format
- e-Book
- Location
- Online
Antiangiogenic Agents in Cancer Therapy
https://libcat.nshealth.ca/en/permalink/provcat40632
edited by Beverly A. Teicher, Lee M. Ellis.
(2nd ed.)
--Totowa, NJ:
Humana Press
, c2008.
- Available Online
- View e-Book
- Location
- Online
Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge. Antiangiogenic Agents in Cancer Therapy, Second Edition provides a current, up-dated perspective on the state of the art…
- Available Online
- View e-Book
- Other Authors
- Teicher, Beverly A
- Ellis, Lee M
- Responsibility
- edited by Beverly A. Teicher, Lee M. Ellis
- Edition
- 2nd ed.
- Place of Publication
- Totowa, NJ
- Publisher
- Humana Press
- Date of Publication
- c2008
- Physical Description
- 1 online resource (xviii, 559 p. : ill.)
- Series Title
- Cancer drug discovery and development
- ISBN
- 9781597451840
- 9781588298706 (print ed.)
- Subjects (MeSH)
- Angiogenesis Inhibitors - therapeutic use
- Antineoplastic Agents - therapeutic use
- Neoplasms - drug therapy
- Neovascularization, pathologic - drug therapy
- Abstract
- Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge. Antiangiogenic Agents in Cancer Therapy, Second Edition provides a current, up-dated perspective on the state of the art of angiogenesis and therapy with a compendium of scientific findings and approaches to the study of angiogenesis in cancer. Leaders in the field present chapters on such topics as the environmental influences and the genetic and physiologic abnormalities that mediate angiogenesis and its role in the progression of malignant disease, working models of tumor angiogenesis, and the role of angiogenesis inhibition in the therapy of malignant disease in humans. Comprehensive and cutting-edge, Antiangiogenic Agents in Cancer Therapy, Second Edition is an ideal, valuable guide to the most recent advances in the field, and a collection that will be useful for many years to come.
- Contents
- Part I. Basic Biology of Angiogenesis -- Vascular Endothelial Growth Factor Family and Its Receptors -- The Cycle Between Angiogenesis, Perfusion, and Hypoxia in Tumors -- The Role of Integrins in Tumor Angiogenesis -- Tumor Endothelial Cell Abnormalities -- The Extracellular Matrix and VEGF Processing -- Endothelial Precursor Cells -- Role of Pericytes in Angiogenesis -- Newer Vascular Targets -- Chemokines in Angiogenesis -- Angiopoietin/Tie2 Signaling Regulates Tumor Angiogenesis -- Imaging Angiogenesis -- Tumor Blood Vessels -- Lymphatic System in the Pathology of Cancer -- Part II. Translational Research in Tumor Angiogenesis -- VEGF in the Adult -- Normalization of Tumor Vasculature and Microenvironment -- Metronomic Low-Dose Antiangiogenic Chemotherapy in Mice and Man -- Small-Molecule Vascular Disrupting Agents in Cancer Therapy -- Normalization of Tumor Vasculature and Improvement of Radiation Response by Antiangiogenic Agents -- Challenges in Translating Antiangiogenic Therapy from the Bench to Bedside -- Regulation of Angiogenesis in Cancer and Its Therapeutic Implications -- Part III. Antiangiogenic Therapy in the Clinical Trial Results and Future Directions -- Angiogenesis and Angiogenesis Inhibition in Sarcomas -- Antiangiogenesis Agents in Colorectal Cancer -- Antiangiogenic Therapy for Primary CNS Tumors -- Angiogenesis Inhibitors for the Treatment of Lung Cancer -- Antiangiogenic Therapy of Renal Cell Carcinoma -- Antiangiogenesis Therapies in Gynecologic Malignancies -- Antiangiogenic Agents in Myeloid Malignancies -- Angiogenesis in Malignant and Non-Malignant Pediatric Tumors -- Prognostic and Predictive Significance of Surrogate Biomarkers of Angiogenesis -- Endpoints for the Determination of Efficacy of Antiangiogenic Agents in Clinical Trials -- The Role of Imaging in the Clinical Development of Antiangiogenic Agents.
- Format
- e-Book
- Location
- Online
Camptothecins in Cancer Therapy
https://libcat.nshealth.ca/en/permalink/provcat28891
edited by Val R. Adams, Thomas G. Burke.
--Totowa, NJ:
Humana Press
, c2005.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Author
- Adams, Val R
- Other Authors
- Burke, Thomas G
- Responsibility
- edited by Val R. Adams, Thomas G. Burke
- Place of Publication
- Totowa, NJ
- Publisher
- Humana Press
- Date of Publication
- c2005
- Series Title
- Cancer drug discovery and development
- ISBN
- 9781592598663
- Subjects (MeSH)
- Camptothecin - pharmacology
- Camptothecin - therapeutic use
- Neoplasms - drug therapy
- Antineoplastic Agents, Phytogenic - therapeutic use
- Format
- e-Book
- Location
- Online
Cancer and Cardiovascular Disease : A Concise Clinical Atlas
https://libcat.nshealth.ca/en/permalink/provcat42613
Syed Wamique Yusuf, Jose Banchs, editors.
--Cham:
Springer
, c2018.
- Available Online
- View e-Book
- Location
- Online
The atlas provides a clear, concise, yet comprehensive review of common cardiovascular diseases occurring in patients with cancer. Cancer and cardiovascular disease are the two most common conditions worldwide. In clinical practice we frequently encounter patients who have established cardiovascular disease and subsequently develop cancer or are survivors of cancer with subsequent cardiovascular complications related to chemotherapy and or radiation. Most of the chapters are case based, followe…
- Available Online
- View e-Book
- Other Authors
- Yusuf, Syed Wamique
- Banchs, Jose
- Responsibility
- Syed Wamique Yusuf, Jose Banchs, editors
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- c2018
- Physical Description
- 1 online resource (xii, 212 p.) : 351 illus., 198 illus. in color
- ISBN
- 9783319620886
- 9783319620862 (print ed.)
- 9783319620879 (print ed.)
- Subjects (MeSH)
- Cardiovascular Diseases - complications
- Neoplasms - complications
- Antineoplastic Agents - adverse effects
- Specialty
- Cardiology
- Medical Oncology
- Abstract
- The atlas provides a clear, concise, yet comprehensive review of common cardiovascular diseases occurring in patients with cancer. Cancer and cardiovascular disease are the two most common conditions worldwide. In clinical practice we frequently encounter patients who have established cardiovascular disease and subsequently develop cancer or are survivors of cancer with subsequent cardiovascular complications related to chemotherapy and or radiation. Most of the chapters are case based, followed by images and a discussion on current (evidence based, wherever available) investigations and treatment outline.
- Contents
- 1. Global Burden of Cancer and Cardiovascular Disease -- 2. Utility of Cardiac Ultrasound Imaging in Oncology, a Case Based Illustration -- 3. Cancer Treatment-Related Cardiotoxicity: Role of Cardiovascular Magnetic Resonance Imaging -- 4. Imaging to Diagnose Myocarditis, Cardiomyopathy, Tumor and Thrombus -- 5. Takotsubo Syndrome and Cancer -- 6. Mechanism and Prevention of Cardiomyopathy Due to Chemotherapy -- 7. Radiation Related Cardiovascular Disease -- 8. Acute Coronary Syndrome in Patients with Cancer -- 9. Arterial Complications in Patients with Cancer -- 10. Carotid Artery Disease in Patients with Cancer -- 11. Venous Diseases in Malignancy -- 12. Cardiac Masses -- 13. Surgical Treatment for Cardiac Sarcomas -- 14. Cardiac Arrhythmia and Device Management in Patients with Cancer -- 15. Endocarditis -- 16. Pericardial Disease, Constrictive Pericarditis and Restrictive Cardiomyopathy in Patients with Cancer -- 17. Exercise Therapy and Cardiovascular Benefits in Patients with Cancer.
- Format
- e-Book
- Publication Type
- Atlas
- Location
- Online
Cancer Chemotherapy in Clinical Practice
https://libcat.nshealth.ca/en/permalink/provcat30817
Terry Priestman.
(2nd ed.)
--London:
Springer
, c2012.
- Available Online
- View e-Book
- Location
- Online
The last decade has seen many dramatic changes in cancer chemotherapy, with the introduction of a number of new forms of treatment as well as important developments in the more traditional fields of cytotoxic and hormonal therapy. Now in its second edition, this book summarizes the whole range of systemic cancer therapies and their clinical applications, taking into account new drugs and the emerging concept of personalized therapy. Intended as an introductory text for junior doctors, nurses a…
- Available Online
- View e-Book
- Author
- Priestman, Terrence
- Responsibility
- Terry Priestman
- Edition
- 2nd ed.
- Place of Publication
- London
- Publisher
- Springer
- Date of Publication
- c2012
- Physical Description
- 1 online resource (xiii, 177 p. : 15 ill., 3 ill. in color)
- ISBN
- 9780857297273
- Subjects (MeSH)
- Neoplasms - drug therapy
- Antineoplastic Agents - therapeutic use
- Abstract
- The last decade has seen many dramatic changes in cancer chemotherapy, with the introduction of a number of new forms of treatment as well as important developments in the more traditional fields of cytotoxic and hormonal therapy. Now in its second edition, this book summarizes the whole range of systemic cancer therapies and their clinical applications, taking into account new drugs and the emerging concept of personalized therapy. Intended as an introductory text for junior doctors, nurses and medical students, Cancer Chemotherapy in Clinical Practice is divided into three sections: The Theoretical Basis of Cancer Chemotherapy: following a historical introduction the different treatment modalities are explained in the context of basic tumor biology Practical Aspects of Chemotherapy: covering dosing and drug delivery together with an extensive discussion of possible side-effects and their management Chemotherapy in the Management of Cancer: explaining the place of drug treatment and the outcomes that can be expected from chemotherapy in all the major cancers.
- Contents
- 1. The Theoretical Basis of Cancer Chemotherapy -- 2. Practical aspects of chemotherapy -- 3. Part III: Chemotherapy in the management of cancer
- Format
- e-Book
- Location
- Online
Cancer Drug Resistance
https://libcat.nshealth.ca/en/permalink/provcat28300
edited by Beverly A. Teicher.
--Totowa, NJ:
Humana Press
, c2006.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Author
- Teicher, Beverly A
- Responsibility
- edited by Beverly A. Teicher
- Place of Publication
- Totowa, NJ
- Publisher
- Humana Press
- Date of Publication
- c2006
- Series Title
- Cancer drug discovery and development
- ISBN
- 9781597450355
- Subjects (MeSH)
- Antineoplastic Agents - therapeutic use
- Drug Resistance, Neoplasm
- Format
- e-Book
- Location
- Online
Cancer immunotherapy : immune suppression and tumor growth
https://libcat.nshealth.ca/en/permalink/provcat27591
Pendergast, George C.
--Amsterdam, Netherlands:
Elsevier Academic Press
, 2007.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Author
- Pendergast, George C
- Other Authors
- Jaffee, Elizabeth M
- Place of Publication
- Amsterdam, Netherlands
- Publisher
- Elsevier Academic Press
- Date of Publication
- 2007
- Physical Description
- 409 p.
- ISBN
- 9780080521855
- Subjects (MeSH)
- Antineoplastic Agents - therapeutic use
- Immunotherapy
- Neoplasms - therapy
- Contents
- Cancer immunoediting: from immune surveillance to immune escape / Ryungsa Kim -- Immunosurveillance: innate and adaptive antitumor immunity / Masahisa Jinushi and Glenn Dranoff -- Cytokine regulation of immune tolerance to tumors / Ming O. Li and Richard A. Flavell -- Immunological sculpting: natural killer cell receptors and ligands / David A. Sallman and Julie Y. Djeu -- Immune escape: immunosuppressive networks / Shuang Wei, Alfred Chang, and Weiping Zou -- Cytotoxic chemotherapy in clinical treatment of cancer / Rajesh Thirumaran, George C. Prendergast, and Paul B. Gilman -- Targeted therapeutics in cancer treatment / Colin D. Weekes and Manuel Hidalgo -- Concepts in pharmacology and toxicology / Richard A. Westhouse and Bruce D. Car -- Cancer immunotherapy: challenges and opportunities / Andrew J. Lepisto, John R. McKolanis, and Olivera J. Finn -- Cancer vaccines / Freda K. Stevenson ... [et al.] -- Immunotherapy and cancer therapeutics: why partner? / Leisha A. Emens and Elizabeth M. Jaffee -- Immune stimulatory features of classical chemotherapy / Robbert G. van der Most, Anna K. Nowak, and Richard A. Lake -- Dendritic cells and coregulatory signals: immune checkpoint blockade to stimulate immunotherapy / Drew Pardoll -- Regulatory T cells in tumor immunity: role of toll-like receptors / Rong-Fu Wang -- Tumor-associated macrophages in cancer growth and progression / Alberto Mantovani, Paola Allavena and Antonio Sica -- Tumor-associated myeloid-derived suppressor cells / Stephanie K. Bunt ... [et al.] -- Programmed death ligand-1 and galectin-1: pieces in the puzzle of tumor-immune escape / Gabriel A. Rabinovich and Thomas F. Gajewski -- Indoleamine 2,3-dioxygenase in immune escape: regulation and therapeutic inhibition / Alexander J. Muller and George C. Prendergast -- Arginase, nitric oxide synthase, and novel inhibitors of L-arginine metabolism in immune modulation / Susanna Mandruzzato, Simone Mocellin, and Vincenzo Bronte.
- Format
- e-Book
- Location
- Online
Cancer Management in Man : Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures
https://libcat.nshealth.ca/en/permalink/provcat28897
edited by Boris R. Minev.
--Dordrecht ; New York:
Springer Science+Business Media
, c2011.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Author
- Minev, Boris R
- Responsibility
- edited by Boris R. Minev
- Place of Publication
- Dordrecht ; New York
- Publisher
- Springer Science+Business Media
- Date of Publication
- c2011
- Series Vol.
- 13
- Series Title
- Cancer growth and progression
- ISBN
- 9789048197040
- Subjects (MeSH)
- Antineoplastic Agents - therapeutic use
- Neoplasms - drug therapy
- Neoplasms - therapy
- Subjects (LCSH)
- Oncology
- Format
- e-Book
- Location
- Online
Cancer Proteomics : From Bench to Bedside
https://libcat.nshealth.ca/en/permalink/provcat40631
edited by Sayed S. Daoud.
--Totowa, NJ:
Humana Press
, c2008.
- Available Online
- View e-Book
- Location
- Online
Over the past 20 years or so, there have been tremendous advances in our understanding of how normal cells transform to cancer and the importance of signaling pathways in cancer initiation and progression. Therefore, proteomics technologies must be improved for more global analysis of protein content of cells, tissues and body fluids as well as the posttranslational modifications to allow for proper detections and validation. In Cancer Proteomics, the authors collectively provide the current st…
- Available Online
- View e-Book
- Other Authors
- Daoud, Sayed S
- Responsibility
- edited by Sayed S. Daoud
- Place of Publication
- Totowa, NJ
- Publisher
- Humana Press
- Date of Publication
- c2008
- Physical Description
- 1 online resource (xii, 264 p. : 5 illus. in color)
- Series Title
- Cancer drug discovery and development
- ISBN
- 9781597451697
- 9781588298584 (print ed.)
- Subjects (MeSH)
- Antineoplastic Agents
- Biomarkers, Tumor
- Neoplasms
- Proteomics - methods
- Abstract
- Over the past 20 years or so, there have been tremendous advances in our understanding of how normal cells transform to cancer and the importance of signaling pathways in cancer initiation and progression. Therefore, proteomics technologies must be improved for more global analysis of protein content of cells, tissues and body fluids as well as the posttranslational modifications to allow for proper detections and validation. In Cancer Proteomics, the authors collectively provide the current status of proteomics in cancer therapy and offers the existing technologies used in proteomics that allow for protein profiling and for the identification of druggable targets in human samples. Mass spectrometry based protein characterization and protein microarrays hold great promise of predicting response to specific drugs in cancer therapy. Insightful to the reader with broad perspectives on topics related to the use of proteomic strategies in cancer therapy, Cancer Proteomics offers anticipated challenges that may arise from its application in daily practice.
- Contents
- Part I. Proteomics Technologies -- Current and Emerging Mass Spectrometry Instrumentation and Methods for Proteomic Analyses -- Part II. Cell Signaling Proteomics -- Integration of Genomics and Proteomics in Dissecting p53 Signaling -- Proteomic Profiling of Tyrosine Kinases as Pharmacological Endpoints for Targeted Cancer Therapy -- Part III. Tumor Proteomics -- Oncoproteomics for Personalized Management of Cancer -- Application of Serum and Tissue Proteomics to Understand and Detect Solid Tumors -- Insight on Renal Cell Carcinoma Proteome -- Proteomics in Lung Cancer -- Proteomic Strategies of Therapeutic Individualization and Target Discovery in Acute Myeloid Leukemia -- New Tumor Biomarkers: Practical Considerations Prior to Clinical Application -- Part IV. Bioinformatics and Regulatory Aspects of Proteomics -- Annotating the Human Proteome: From Establishing a Parts List to a Tool for Target Identification -- Regulatory Issues in the Co-Development of Oncology Drugs and Proteomic Tests: An Overview.
- Format
- e-Book
- Location
- Online
Cancer Stem Cells : Novel Concepts and Prospects for Tumor Therapy
https://libcat.nshealth.ca/en/permalink/provcat40599
O.D. Wiestler, B. Haendler, D. Mumberg, editors.
--Berlin, Heidelberg:
Springer
, c2007.
- Available Online
- View e-Book
- Location
- Online
This book describes the recent developments in the emerging field of cancer stem cells. Their possible impact for the identification of novel treatment paradigms for cancer are discussed.
- Available Online
- View e-Book
- Other Authors
- Wiestler, O.D
- Haendler, B
- Mumberg, D
- Other Authors
- Ernst Schering Research Foundation
- Responsibility
- O.D. Wiestler, B. Haendler, D. Mumberg, editors
- Place of Publication
- Berlin, Heidelberg
- Publisher
- Springer
- Date of Publication
- c2007
- Physical Description
- 1 online resource (xvi, 263 p.)
- Series Vol.
- 2006/5
- ISBN
- 9783540708537
- 9783540708520 (print ed.)
- ISSN
- 0947-6075
- Subjects (MeSH)
- Antineoplastic Agents - pharmacology
- Neoplasms - prevention & control
- Neoplastic Stem Cells - drug effects
- Neoplastic stem cells - pathology
- Signal transduction - physiology
- Abstract
- This book describes the recent developments in the emerging field of cancer stem cells. Their possible impact for the identification of novel treatment paradigms for cancer are discussed.
- Contents
- Niche for Normal and Cancer Stem Cells -- c-Myc and Activated Ras During Skin Tumorigenesis: Cooperation at the Cancer Stem Cell Level? -- Wnt Signaling in Stem Cells and Lung Cancer -- Bone Morphogenetic Proteins Regulate Tumorigenicity in Human Glioblastoma Stem Cells -- Strategies to Induce Nuclear Reprogramming -- The Intestinal Stem Cell Niche Studied Through Conditional Transgenesis -- The Migrating Cancer Stem Cells Model - A Conceptual Explanation of Malignant Tumour Progression -- Bone Marrow Niche and Leukemia -- Breast Stem Cells and Cancer -- Prostate Cancer Stem Cells: A Target for New Therapies -- The Hedgehog Signaling Network, Mammary Stem Cells, and Breast Cancer: Connections and Controversies -- Strategies to Eliminate Cancer Stem Cells -- DNA Repair in Stem Cell Maintenance and Conversion to Cancer Stem Cells -- Tumorigenic Epithelial Stem Cells and Their Normal Counterparts.
- Format
- e-Book
- Publication Type
- Congress
- Location
- Online
Cardiac Management of Oncology Patients : Clinical Handbook for Cardio-Oncology
https://libcat.nshealth.ca/en/permalink/provcat39229
Gonzalo Baron Esquivias, Riccardo Asteggiano, editors.
--Cham:
Springer
, c2015.
- Available Online
- View e-Book
- Location
- Online
In recent years, progress in oncologic therapy has achieved important goals and a consequent prognostic improvement for patients with malignancy, but cardiac toxicity is often a concern and can have long-term functional or structural effects on the heart. This book is written for the cardiologist working in a clinical environment without support from a specific specialized cardio-oncologist team, and who are called to perform a clinical consultation to evaluate a cardiac condition and the eligi…
- Available Online
- View e-Book
- Other Authors
- Baron Esquivias, Gonzalo
- Asteggiano, Riccardo
- Responsibility
- Gonzalo Baron Esquivias, Riccardo Asteggiano, editors
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- c2015
- Physical Description
- 1 online resource (ix, 259 p. : 65 illus., 58 illus. in color)
- ISBN
- 9783319158082
- 9783319158075 (print ed.)
- Subjects (MeSH)
- Antineoplastic Agents - toxicity
- Heart diseases - etiology
- Heart Diseases - therapy
- Neoplasms - complications
- Abstract
- In recent years, progress in oncologic therapy has achieved important goals and a consequent prognostic improvement for patients with malignancy, but cardiac toxicity is often a concern and can have long-term functional or structural effects on the heart. This book is written for the cardiologist working in a clinical environment without support from a specific specialized cardio-oncologist team, and who are called to perform a clinical consultation to evaluate a cardiac condition and the eligibility for a patient to receive chemotherapy or radiotherapy. Cardiac Management of Oncology Patients: Clinical Handbook for Cardio-Oncology is also designed for oncologists and cardiologists to evaluate if a cancer treatment has produced toxic effects on a patient who has either recently or historically been treated with chemo or radiotherapy. The reader will discover more about the cardiac damage potentially created by the oncologic therapy that they are considering for the treatment of their patients.
- Contents
- 1 Introduction -- 2 Physiopathology and Toxic Heart Effects of Chemotherapy Drugs -- 3 Radiotherapy Heart Effects -- 4 Cardiac Imaging Technology in Cardio-oncology -- 5 Evaluation of the Oncologic Patient Before, During, and After Chemotherapy -- 6 Specific Clinic Problems in Cancer Therapy Cardiac Toxicity Complications -- 7 Synthetic Tables.
- Format
- e-Book
- Location
- Online
Cardio-Oncology : The Clinical Overlap of Cancer and Heart Disease
https://libcat.nshealth.ca/en/permalink/provcat41453
Gretchen G. Kimmick, Daniel J. Lenihan, Douglas B. Sawyer, Erica L. Mayer, Dawn L. Hershman, editors.
--Cham:
Springer
, 2017.
- Available Online
- View e-Book
- Location
- Online
Co-edited and written by an interdisciplinary team of experts in oncology and cardiology, this book is a clinically useful resource on these overlapping topics: Cardiac complications in patients receiving cancer therapy; The treatment of cancer in patients with cardiovascular disease; The treatment of cardiovascular disease in patients with cancer. When relevant to medical practice, epidemiology and basic science are also included in the discussion and each chapter is written by an oncologist a…
- Available Online
- View e-Book
- Other Authors
- Kimmick, Gretchen G
- Lenihan, Daniel J
- Sawyer, Douglas B
- Mayer, Erica L
- Hershman, Dawn L
- Responsibility
- Gretchen G. Kimmick, Daniel J. Lenihan, Douglas B. Sawyer, Erica L. Mayer, Dawn L. Hershman, editors
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- 2017
- Physical Description
- 1 online resource (xv, 319 pages) : 55 illus., 49 illus. in color
- ISBN
- 9783319430966
- 9783319430942 (print ed.)
- Subjects (MeSH)
- Antineoplastic Agents - adverse effects
- Cardiotoxicity - complications
- Cardiovascular Diseases - complications
- Cardiovascular Diseases - prevention & control
- Neoplasms - complications
- Neoplasms - drug therapy
- Abstract
- Co-edited and written by an interdisciplinary team of experts in oncology and cardiology, this book is a clinically useful resource on these overlapping topics: Cardiac complications in patients receiving cancer therapy; The treatment of cancer in patients with cardiovascular disease; The treatment of cardiovascular disease in patients with cancer. When relevant to medical practice, epidemiology and basic science are also included in the discussion and each chapter is written by an oncologist and a cardiologist. Additionally, the chapters follow a similar format to make the book truly interdisciplinary, user-friendly, and clinically applicable to specialists and non-specialists who care for patients with both cancer and cardiovascular disease.
- Contents
- 1. Epidemiology of Cardio-Oncology -- 2. Cardiotoxicity of Anticancer Therapies -- 3. Screening and Monitoring for Cardiotoxicity During Cancer Treatment -- 4. Management of Chemotherapy-Associated Cardiomyopathy -- 5. Treatment of Hypertension in Patients Receiving Cancer Therapy -- 6. Preoperative and Pre-transplant Cardiac Evaluation in the Cancer Patient -- 7. Radiation Therapy and Cardiotoxicity -- 8. Management of Patients with Coronary Disease and Cancer: Interactions Between Cancer, Cancer Treatment, and Ischemia -- 9. Vascular Complications of Cancer and Cancer Therapy -- 10. Breast Cancer Cardio-Oncology -- 11. Cardiac Toxic Chemotherapy and Cancer Survivorship -- 12. Geriatric Cardio-oncology -- 13. Future Clinical and Professional Directions in Cardio-oncology.
- Format
- e-Book
- Location
- Online
Checkpoint Controls and Targets in Cancer Therapy
https://libcat.nshealth.ca/en/permalink/provcat29742
edited by Zahid H. Siddik.
--Totowa, NJ:
Humana Press
, c2009.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Author
- Siddik, Zahid H
- Responsibility
- edited by Zahid H. Siddik
- Place of Publication
- Totowa, NJ
- Publisher
- Humana Press
- Date of Publication
- c2009
- Series Title
- Cancer drug discovery and development
- ISBN
- 9781607611783
- Subjects (MeSH)
- Antineoplastic Agents - pharmacology
- Cell Cycle Checkpoints
- Cell Cycle - drug effects
- Neoplasms - drug therapy
- Format
- e-Book
- Location
- Online
Chemotherapy and immunotherapy guidelines and recommendations for practice
https://libcat.nshealth.ca/en/permalink/provcat43752
edited by MiKaela Olsen, Kristine B. LeFebvre, and Kelly J. Brassil.
--Pittsburgh, PA:
Oncology Nursing Society
, c2019.
- Available Online
- View e-Book
- Location
- Online
- Available Online
- View e-Book
- Other Authors
- Olsen, MiKaela
- Responsibility
- edited by MiKaela Olsen, Kristine B. LeFebvre, and Kelly J. Brassil.
- Alternate Title
- Chemotherapy and immunotherapy guidelines & recommendations for practice
- Place of Publication
- Pittsburgh, PA
- Publisher
- Oncology Nursing Society
- Date of Publication
- c2019
- Physical Description
- 1 online resource
- ISBN
- 9781635930214
- Subjects (MeSH)
- Antineoplastic Agents
- Immunotherapy
- Neoplasms - nursing
- Neoplasms - therapy
- Specialty
- Medical Oncology
- Pharmacology
- Format
- e-Book
- Publication Type
- Practice Guideline
- Location
- Online
Chemotherapy and Immunotherapy in Urologic Oncology : A Guide for the Advanced Practice Provider
https://libcat.nshealth.ca/en/permalink/provcat46364
Edouard J. Trabulsi, Costas D. Lallas, Anne E. Lizardi-Calvaresi, editors.
--Cham:
Springer
, c2021.
- Available Online
- View e-Book
- Access
- NEW Springer 2021
- Location
- Online
This book is designed to familiarize clinical practitioners in systemic therapy options and medical management of urologic malignancies including prostate cancer, bladder and upper tract urothelial carcinoma, and renal cell carcinoma. Organized by organ system, the text highlights new therapies such as novel forms of androgen deprivation, cytotoxic chemotherapy, immune check point and immunomodulatory agents, and targeted therapies. Written by experts in the field, the book also reviews current…
- Available Online
- View e-Book
- Other Authors
- Trabulsi, Edouard J.
- Lallas, Costas D.
- Lizardi-Calvaresi, Anne E.
- Responsibility
- Edouard J. Trabulsi, Costas D. Lallas, Anne E. Lizardi-Calvaresi, editors
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- c2021
- Physical Description
- 1 online resource (xiv, 307 p.) : 22 illus., 19 illus. in color
- ISBN
- 9783030520212
- 9783030520205 (Print ed.)
- 9783030520229 (Print ed.)
- Subjects (MeSH)
- Antineoplastic Agents - therapeutic use
- Urologic Neoplasms - drug therapy
- Immunotherapy - methods
- Abstract
- This book is designed to familiarize clinical practitioners in systemic therapy options and medical management of urologic malignancies including prostate cancer, bladder and upper tract urothelial carcinoma, and renal cell carcinoma. Organized by organ system, the text highlights new therapies such as novel forms of androgen deprivation, cytotoxic chemotherapy, immune check point and immunomodulatory agents, and targeted therapies. Written by experts in the field, the book also reviews current chemotherapy and immunotherapy regimens for genitourinary malignancies and discusses indications, outcomes, and toxicities, as well as clinical trial concepts. Each of the book’s chapters offers a bulleted box of clinical pearls on the particular role of the APP. Chemotherapy and Immunotherapy in Urologic Oncology: A Guide for the Advanced Practice Provider is a resource for urologists, uro-radiologists, medical clinicians and family practitioners alike, familiarizing its audiences with systemic therapy regimens for urologic malignancies, as well as their expected outcomes and side effects. .
- Contents
- Introduction: Integration of APP into Urologic Oncology Practice -- Part I. Prostate Cancer -- Overview and Active Surveillance of Prostate Cancer -- Monitoring and Managing Men Following Initial Treatment of Prostate Cancer -- Radical Prostatectomy and Survivorship after Radical Prostatectomy -- Multimodal Treatment Plans in Prostate Cancer -- Radiotherapy for Prostate Cancer -- Androgen Deprivation Treatment -- Second Generation Androgen Targeted Agents -- Chemotherapy and prostate cancer -- Radiopharmaceuticals for Prostate Cancer -- Immunotherapy and Novel Agents on the Horizon for the Treatment of Prostate Cancer -- Part II. Bladder Cancer -- Bladder Cancer: Overview, Epidemiology, Initial Presentation and Diagnosis -- Intravesical Therapy for Non Muscle Invasive Urothelial Carcinoma -- Bladder Cancer: Muscle Invasive Disease, Neoadjuvant Chemotherapy, and Radical Cystectomy -- Chemoradiation Bladder Preservation -- Metastatic Bladder Cancer and the Use of Cisplatin Chemotherapy -- Immunotherapy for Metastatic Urothelial Cancer -- Novel and experimental Strategies in the Treatment of Metastatic Urothelial Carcinoma -- Upper Tract Urothelial Carcinoma -- Part III. Kidney Cancer -- Kidney Cancer and Its Treatment -- Targeted Therapies for Treatment of Metastatic Renal Cell Carcinoma -- Immune Therapies for Metastatic Kidney Cancer -- Novel Therapies for Renal Cell Carcinoma -- Part IV. Other Malignancies -- Testicular Cancer -- Penile Cancer.
- Access
- NEW Springer 2021
- Format
- e-Book
- Location
- Online
Chemotherapy and Pharmacology for Leukemia in Pregnancy : Guidelines and Strategies for Best Practices
https://libcat.nshealth.ca/en/permalink/provcat46361
Carolina Witchmichen Penteado Schmidt, Kaléu Mormino Otoni, editors.
--Cham:
Springer
, c2021.
- Available Online
- View e-Book
- Access
- NEW Springer 2021
- Location
- Online
In response to the complexity involved in treating leukemia during pregnancy, and the need to find the most efficient treatment possible without harming the fetus, this book offers essential guidelines for institutions and practitioners alike. Pursuing a comprehensive approach, the book addresses a broad range of subjects, including: pregnancy and its characteristics; staging, pathology, morbidity and what to expect in each type of leukemia; chemotherapy for leukemia in pregnant women with comp…
- Available Online
- View e-Book
- Other Authors
- Schmidt, Carolina Witchmichen Penteado
- Otoni, Kaléu Mormino
- Responsibility
- Carolina Witchmichen Penteado Schmidt, Kaléu Mormino Otoni, editors
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- c2021
- Physical Description
- 1 online resource (x, 210 p.) : 4 illus., 2 illus. in color
- ISBN
- 9783030540586
- 9783030540579 (Print ed.)
- 9783030540593 (Print ed.)
- Subjects (MeSH)
- Antineoplastic Agents - therapeutic use
- Leukemia - drug therapy
- Maternal-Fetal Exchange - drug effects
- Pregnancy Complications, Neoplastic
- Specialty
- Medical Oncology
- Obstetrics
- Pharmacology
- Abstract
- In response to the complexity involved in treating leukemia during pregnancy, and the need to find the most efficient treatment possible without harming the fetus, this book offers essential guidelines for institutions and practitioners alike. Pursuing a comprehensive approach, the book addresses a broad range of subjects, including: pregnancy and its characteristics; staging, pathology, morbidity and what to expect in each type of leukemia; chemotherapy for leukemia in pregnant women with complete trials; dose adjustment of chemotherapy for leukemia in pregnancy based on serum dosages; and pharmacokinetics and pharmacodynamics for this unique group of patients. In turn, subsequent chapters focus on protecting the fetus and neonatal management regarding chemotherapy for leukemia in pregnancy, including the treatment and risks for the fetus (for each type of leukemia), intrathecal therapy and its effects on the fetus; supportive drugs, antibiotics and antifungals for pregnant patients during chemotherapy, including intervention and dose adjustments; palliative care for women with leukemia in pregnancy; breastfeeding during treatment for leukemia; pharmacological aspects of supplements, vitamins and nutrition in pregnancy during leukemia treatment; and more. Combining contributions from highly qualified hematology professionals, who have pooled their knowledge to address the treatment of virtually every aspect of leukemia in pregnancy, the book is aimed at a complete pharmacological treatment, including guidelines and trials. It is a must-have not only for institutions providing care for hematology patients, but also for residency programs, research institutions, and professionals in areas that involve leukemia treatment for pregnant women — e.g. hematology, neonatology, obstetrics clinics, intensive medicine and critical care units.
- Contents
- Introduction -- Clinical Perspectives For Leukemia Treatment During Pregnancy -- Chemotherapy Protocols For Leukemia During Pregnancy -- Pharmacokinetics And Pharmacodynamics Of Chemotherapy For Leukemia In Pregnancy -- Clinical Care Of The Fetus And The Mother: Obstetrics Management For Patients On Treatment For Leukemia -- Antibiotic And Antifungal Therapies During Leukemia Treatment In Pregnancy -- Transfusion In Pregnant Patients Receiving Treatment For Leukemia -- Dose Adjustment Of Chemotherapy For Leukemia In Pregnancy Based On Serum Dosages -- Supportive Drugs in Leukemia Treatment During Pregnancy -- Breastfeeding During Chemotherapy Treatment For Leukemia -- Palliative Care For Patients With Leukemia During Pregnancy.
- Access
- NEW Springer 2021
- Format
- e-Book
- Location
- Online
Chemotherapy in Neonates and Infants : Pharmacological Oncology for Children Under 1 Year Old
https://libcat.nshealth.ca/en/permalink/provcat42571
Carolina Witchmichen Penteado Schmidt.
--Cham:
Springer
, c2018.
- Available Online
- View e-Book
- Location
- Online
This book provides a comprehensive overview of pediatric oncology, discussing drug therapy and treatment in children under the age of 1 year. It is the first volume to focus on chemotherapy in newborns and infants, especially the daily clinical practice and treatment protocols. Intended as a practical manual, it addresses all the major topics related to pediatric oncology in an accessible and easy-to-use format. It examines topics in pediatric oncology therapeutics, including drug metabolism, e…
- Available Online
- View e-Book
- Responsibility
- Carolina Witchmichen Penteado Schmidt
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- c2018
- Physical Description
- 1 online resource (xix, 198 p.) : 8 illus. in color
- ISBN
- 9783319705910
- 9783319705903 (print ed.)
- 9783319705927 (print ed.)
- Subjects (MeSH)
- Antineoplastic Agents - pharmacology
- Drug-Related Side Effects and Adverse Reactions - prevention & control
- Infant
- Infant, Newborn
- Neoplasms - drug therapy
- Specialty
- Medical Oncology
- Pediatrics
- Pharmacology
- Abstract
- This book provides a comprehensive overview of pediatric oncology, discussing drug therapy and treatment in children under the age of 1 year. It is the first volume to focus on chemotherapy in newborns and infants, especially the daily clinical practice and treatment protocols. Intended as a practical manual, it addresses all the major topics related to pediatric oncology in an accessible and easy-to-use format. It examines topics in pediatric oncology therapeutics, including drug metabolism, excretion, toxicity, drugs that can be used for each week or month of the patient's life, dose adjustment and treatment protocols. Chemotherapy in Neonates and Infants focuses on the safe treatment of children in the first year of life, and is aimed at pediatric oncology/hematology institutions, clinics and departments. It is particularly valuable for researchers, pediatric oncology physicians, pediatric and neonatology physicians, oncology pharmacists and the other healthcare professionals directly involved in the chemotherapy of neonates and infants.
- Contents
- 1. Introduction -- 2. Protocols Used in Chemotherapy Treatment of Neonates and Infants -- 3. Pharmacokinetics and Pharmacodynamics of Chemotherapy Drugs in Neonates and Infants -- 4. Peculiarities of Most Commonly Used Chemotherapy Drugs in Neonates and Infants -- 5. Adjuvant Drugs Used in Chemotherapy for Neonates and Infants -- 6. Drug Interactions in Neonates and Infants -- 7. Toxicity -- 8. Tumor Lysis in Neonates and Infants -- 9. Chemotherapy in Neonates and Infants with Cancer and Other Congenital Diseases: Down Syndrome and HIV -- 10. Stem Cell Transplantation in Neonates and Infants.
- Format
- e-Book
- Location
- Online
Chronic Myeloid Leukemia
https://libcat.nshealth.ca/en/permalink/provcat40239
R©diger Hehlmann, editor.
--Cham:
Springer
, c2016.
- Available Online
- View e-Book
- Location
- Online
This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management o…
- Available Online
- View e-Book
- Other Authors
- Hehlmann, R©diger
- Responsibility
- R©diger Hehlmann, editor
- Place of Publication
- Cham
- Publisher
- Springer
- Date of Publication
- c2016
- Physical Description
- 1 online resource (x, 255 p. : 40 illus., 39 illus. in color)
- Series
- Hematologic Malignancies
- Series Title
- Hematologic malignancies (Series)
- ISBN
- 9783319331980
- 9783319331973 (print ed.)
- ISSN
- 2197-9766
- Subjects (MeSH)
- Antineoplastic Agents - therapeutic use
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology
- Abstract
- This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the forthcoming impact of availability of generic imatinib.
- Contents
- 1 Cytogenetics of Chronic Myeloid Leukemia (CML) -- 2 The Biology and Pathogenesis of Chronic Myeloid Leukemia -- 3 The Choice of First-Line Chronic Myelogenous Leukemia Treatment -- 4 A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia -- 5 Management of Adverse Events Associated with ATP-Competitive BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia -- 6 Standardization of Molecular Monitoring for Chronic Myeloid Leukemia -- 7 Epidemiology of Chronic Myeloid Leukemia -- 8 Prognostic Scores for Patients with Chronic Myeloid Leukemia Under Particular Consideration of Disease-Specific Death -- 9 Response-Related Predictors of Survival in CML -- 10 CML Blast Crisis: Implications and Management -- 11 Managing Pregnancy in Chronic Myeloid Leukemia -- 12 The Role of Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia -- 13 Discontinuation or Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response -- 14 The Interferon Alpha Revival in CML -- 15 Changing the Cost of Care for Chronic Myeloid Leukemia: The Availability of Generic Imatinib in the USA and the EU.
- Format
- e-Book
- Location
- Online
